Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.91 USD | +7.62% | +4.91% | +17.19% |
05-14 | Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating | MT |
05-14 | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.19% | 457M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Transcript : Fulcrum Therapeutics, Inc., Q3 2023 Earnings Call, Nov 07, 2023